Three-year data for Iluvien found a single implant delayed recurrence of noninfectious posterior uveitis and reduced uveitis symptoms, according to a press release from Alimera Sciences.
The phase 3 clinical trial showed the median time to first recurrence of noninfectious uveitis affecting the posterior of the eye was 657 days, or 94 weeks, in patients treated with Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) compared with 70.5 days, or 10 weeks, in those treated with sham (P < .001). In addition, the Iluvien arm saw 1.7 uveitis recurrences compared with 5.3 in the sham arm over 36 months (P < .001), the release said.
“We are very pleased that Iluvien’s continuous microdosing technology not only reduces the recurrence of diabetic macular edema but can provide important and sustained benefits in patients diagnosed with noninfectious posterior uveitis,” Rick Eiswirth, president and CEO of Alimera, said in the release.
The European launch of Iluvien for noninfectious posterior uveitis is planned for the second half of this year.